Long-term safety of tegoprubart in kidney transplant patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This is a long-term follow-up study for people who have already completed a study of the drug tegoprubart after a kidney transplant. It checks how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed an earlier (parent) study that offered you the chance to join this long-term follow-up.
- You must be able to understand the study information and agree to the consent form.
- You must agree not to take part in any other research study while on this treatment.
- If you could become pregnant, you need a negative pregnancy test before starting and must use effective birth control during and for 90 days after the last dose.
- If you are a man with a partner who could become pregnant, you must use effective birth control and not donate sperm for 90 days after the last dose.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new blood test works to monitor kidney health after a transplant. It might help doctors catch problems early without needing a biopsy.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
This study follows older people who received a kidney transplant and are taking a specific immune-suppressing medicine plan (Advagraf/tacrolimus once daily plus mycophenolate and steroids). It may help researchers understand outcomes in real-world patients who match these medication and immune-risk criteria.
This is a study of people who have a specific type of early rejection after a kidney transplant (“acute antibody-mediated rejection”). The study aims to understand what treatments work and why, to improve future care.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.